Key result
Combination lipid-lowering therapy targets residual cardiovascular risk and atherogenic dyslipidemia beyond statin monotherapy.
Answers are grounded in this paper and cite their sources.
Dyslipidemia is one of the most important risk factor for cardiovascular diseases, which are the main cause of death worldwide. There are two treatment options for dyslipidemia that complement each other. Despite the spread of lipid-lowering therapy and its increasing use in clinical practice, a large numbers of patients still remain in high "residual cardiovascular risk." Currently at the forefront of lipid-lowering agents, statins significantly lower LDLcholesterol but in the terms of effect on the levels of triglycerides and HDL-cholesterol there is much less impact. This is a serious problem, especially in patients with atherogenic dyslipidemia, typical for patients with metabolic syndrome. For this reason, high attention has recently been given to combination of lipid-lowering agents. It is also important to mention the important pleiotropic effects of hypolipidemics. This article provides an overview of current lipid-lowering agents, their comparisons as well as new recommendations in the management of dyslipidemia.
No takes yet. Share an insight, caveat, or question.
Pella D Fedacko J (2014) conducted a review in Dyslipidemia. Combination lipid-lowering therapy vs. Individual lipid-lowering therapy (statin monotherapy) was evaluated. Combination lipid-lowering therapy is reviewed alongside statin monotherapy to address residual cardiovascular risk and atherogenic dyslipidemia (no quantitative results reported in abstract).
Synapse has enriched 10 related papers. Consider them for comparative context: